Compare TG Therapeutics Inc (TGTX) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tractor Supply Co — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Tractor Supply Co trades at $36.47 (market cap $18.39B). The key difference: Tractor Supply Co is far larger — about 2.4× TG Therapeutics Inc's market cap, and Tractor Supply Co pays a 2.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TSCO | |
|---|---|---|
Market Cap | $7.64B | $18.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $62.65 |
52-Week Low | $26.94 | $29.14 |
Enterprise Value | $7.84B | $24.70B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
TSCO trades at $36.45, up 5.29% on the day, with a bullish technical signal and strong profitability metrics including a 39.51% ROE. Recent earnings have missed expectations, but the company maintains stable revenue growth and announced strategic initiatives like pet assortment expansion and seasonal events to drive engagement.
The outlook is mixed: valuation appears reasonable with a P/E of 18.38, and insider buying signals confidence, but near-term headwinds include soft discretionary demand and cost pressures. Risks involve execution of turnaround efforts amid economic sensitivity, while analyst consensus leans neutral with a $36.29 price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
